Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 5, 2015, Pages 603-627

  Ballestri, Stefano ^a   Romagnoli, Dante ^b   Nascimbeni, Fabio ^b   Francica, Giampiero ^c   Lonardo, Amedeo ^b  

^a Pavullo Hospital   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Pinetagrande Hospital   (Italy)

Author keywords

cardiovascular risk; cirrhosis; elastography; fatty liver; hepatocellular carcinoma; liver biopsy; liver fibrosis; metabolic syndrome; NASH; portal hypertension; ultrasound

Indexed keywords

B SCAN; CANCER DIAGNOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTRAST ENHANCEMENT; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; EARLY INTERVENTION; ECHOGRAPHY; ELASTOGRAPHY; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH RISK PATIENT; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER RESECTION; LIVER ULTRASONOGRAPHY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PERIODIC MEDICAL EXAMINATION; PORTAL HYPERTENSION; PREDICTION; RADIOFREQUENCY ABLATION; REVIEW; SONOELASTOGRAPHY; SONOGRAPHIC HEPATORENAL INDEX; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; COMPLICATION; DOPPLER FLOWMETRY; LIVER; LIVER NEOPLASMS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; ULTRASONOGRAPHY, DOPPLER;

EID: 84928540539     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1007955     Document Type: Review

References (158)

1. Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42(4): 272-82
2. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59(4): 859-71
3. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332(6037): 1519-23
4. Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1724-45
5. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2014; 1-22
6. Lonardo A, Sookoian S, Chonchol M, et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease -atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19(29): 5177-92
7. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128(7): 1898-906
8. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology 2007; 45(6): 1366-74
9. Day CP, James OF. Steatohepatitis: a tale of two 'hits'?. Gastroenterology 1998; 114(4): 842-5
10. Lonardo A, SH Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Rev Endocrinol Metab 2010; 5(3): 403-23
11. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52(5): 1836-46
12. Lonardo A, Loria P, Argo C, Caldwell S. Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of 'multiorganelle failure':?. Proceedings of a virtual workshop on nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5(2): 135-9
13. Chitturi S, Farrell GC. Fatty liver now, diabetes and heart attack later?. The liver as a barometer of metabolic health. J Gastroenterol Hepatol 2007; 22(7): 967-9
14. Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56(4): 952-64
15. Sertoglu E, Ercin CN, Celebi G, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem 2014; 47(6): 383-8
16. Lonardo A, Ballestri S, Marchesini G, et al. Non-alcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liver Dis 2014.http://dx.doi.org/10.1016/j. dld.2014.09.020
17. Ricchi M, Odoardi MR, Carulli L, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009; 24(5): 830-40
18. Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity (Silver Spring) 2007; 15(12): 3150-8
19. Baumeister SE, Völzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134(1): 85-94
20. Maurantonio M, Ballestri S, Odoardi MR, et al. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Arch Med Res 2011; 42(5): 337-53
21. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a 'bright' liver echopattern. Ital JGastroenterol Hepatol 1997; 29(4): 351-6
22. Lonardo A, Loria P, Leonardi F, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002; 34(3): 204-11
23. Vehmas T, Kaukiainen A, Immonen-Räihä P, et al. Liver echogenicity: relation to systemic blood pressure and other components of the metabolic syndrome. Ultrasound Med Biol 2005; 31(3): 293-9
24. Valtuen'a S, Pellegrini N, Ardigo D, et al. Dietary glycemic index and liver steatosis. Am J Clin Nutr 2006; 84(1): 136-42
25. Holt HB, Wild SH, Wood PJ, et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006; 49(1): 141-8
26. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102(12): 2708-15
27. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012; 32(8): 1242-52
28. Scaglioni F, Marino M, Ciccia S, et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol 2013; 37(4): 353-8
29. Li X, Xia M, Ma H, et al. Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese. PLoS One 2013; 8(7): e65210
30. Mathiesen UL, Franze-n LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34(7): 516-22
31. Palmentieri B, De Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38(7): 485-9
32. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189(6): W320-3
33. Dasarathy S Dasarathy J Khiyami A et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009 51 6 1061-7
34. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123(3): 745-50
35. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54(3): 1082-90
36. Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14(5): 635-7
37. Yajima Y, Ohta K, Narui T, et al. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139(1): 43-50
38. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292(6512): 13-15
39. Ho MC, Lee YH, Jeng YM, et al. Relationship between ultrasound backscattered statistics and the concentration of fatty droplets in livers: an animal study. PLoS One 2013; 8(5): e63543
40. Liang RJ, Wang HH, Lee WJ, et al. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 2007; 17(1): 45-56
41. Zardi EM, De Sio I, Ghittoni G, et al. Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis?. J Clin Gastroenterol 2011; 45(1): 59-63
42. Riley TR, Mendoza A, Bruno MA. Bedside ultrasound can predict non-alcoholic fatty liver disease in the hands of clinicians using a prototype image. Dig DisSci 2006; 51(5): 982-5
43. Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192(4): 909-14
44. Borges VF, Diniz AL, Cotrim HP, et al. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. J Clin Ultrasound 2013; 41(1): 18-25
45. Marshall RH, Eissa M, Bluth EI, et al. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. Am J Roentgenol 2012; 199(5): 997-1002
46. Xia MF, Yan HM, He WY, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity 2012; 20(2): 444-52
47. Martín-Rodríguez JL, Arrebola JP, Jime-nez-Moleo-n JJ, et al. Sonographic quantification of a hepato-renal index for the assessment of hepatic steatosis in comparison with 3T proton magnetic resonance spectroscopy. Eur J Gastroenterol Hepatol 2014; 26(1): 88-94
48. Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009; 58(12): 1724-30
49. Wang JH, Hung CH, Kuo FY, et al. Ultrasonographic quantification of hepatic-renal echogenicity difference in hepatic steatosis diagnosis. Dig Dis Sci 2013; 58(10): 2993-3000
50. Sasso M, Beaugrand M, De Le-dinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE- guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36(11): 1825-35
51. De Le-dinghen V, Vergniol J, Foucher J, et al.Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32(6): 911-18
52. Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32(6): 902-10
53. Masaki K, Takaki S, Hyogo H, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; 43(11): 1182-9
54. Chon YE, Jung KS, Kim SU, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014; 34(1): 102-9
55. De Le-dinghen V, Vergniol J,Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014; 60(5): 1026-31
56. Shen F, Zheng RD, Mi YQ, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 2014; 20(16): 4702-11
57. Friedrich-Rust M, Romen D, Vermehren J, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81(3): e325-31
58. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29(7): 1470-6
59. Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014; 9(3): e91987
60. De Le-dinghen V, Corpechot C, Vergniol J, et al. Steatosis assessment by Cap- using Xl probe. 2014; 60(4): S594A
61. Nascimbeni F, Lebray P, Fedchuk L, et al. Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
62. Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patientswith nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40(10): 1209-22
63. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53(2): 372-84
64. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. Eur J Gastroenterol Hepatol 2009; 21(5): 504-11
65. Moriyasu F, Iijima H, Tsuchiya K, et al. Diagnosis of NASH using delayed parenchymal imaging of contrast ultrasound. Hepatol Res 2005; 33(2): 97-9
66. Iijima H, Moriyasu F, Tsuchiya K, et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007; 37(9): 722-30
67. Yoshikawa S. Iijima H. Saito M. et al. Crucial role of impaired Kupffer cell phagocytosis on the decreased So3nazoid-enhanced echogenicity in a liver of a nonalchoholic steatohepatitis modeli Hepatol Res 2010 40 8):823-31
68. Miyata Y, Miyahara T, Moriyasu F. Decreased accumulation of ultrasound contrast in the liver of nonalcoholic steatohepatitis rat model. World J Gastroenterol 2011; 17(37): 4191-8
69. Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol 2014; 6(7): 496-503
70. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7392-402
71. Bastati N, Feier D, Wibmer A, et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 2014. [Epub ahead of print]
72. Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol 2013; 59(1): 180-2
73. Goyal N, Jain N, Rachapalli V, et al. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009; 64(11): 1056-66
74. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51(3): 433-45
75. Bolondi L, Li Bassi S, Gaiani S, et al. Liver cirrhosis: changes of Doppler waveform of hepatic veins. Radiology 1991; 178(2): 513-16
76. Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver Int 2010; 30(10): 1403-13
77. Staub F, Tournoux-Facon C, Roumy J, et al. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009; 19(8): 1991-7
78. Kim MY, Suk KT, Baik SK, et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology 2012; 56(3): 1053-62
79. Qu EZ, Zhang YC, Li ZY, et al. Contrast-enhanced sonography for quantitative assessment of portal hypertension in patients with liver cirrhosis. J Ultrasound Med 2014; 33(11): 1971-7
80. Liu D, Qian L, Wang J, et al. Hepatic perfusion parameters of contrast-enhanced ultrasonography correlate with the severity of chronic liver disease. Ultrasound Med Biol 2014; 40(11): 2556-63
81. Sekimoto T, Maruyama H, Kiyono S, et al. Hepatic filling rate of a microbubble agent: a novel predictor of long-term outcomes in patients with cirrhosis. Ultrasound Med Biol 2014; 40(9): 2082-8
82. Gerstenmaier JF, Gibson RN. Ultrasound in chronic liver disease. Insights Imaging 2014; 5(4): 441-55
83. Hirooka M, Koizumi Y, Miyake T, et al. Nonalcoholic Fatty Liver Disease: portal Hypertension Due to Outflow Block inPatients without Cirrhosis. Radiology 2014. [Epub ahead of print]
84. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10(11): 666-75
85. Friedrich-Rust M Ong MF Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008 134 4 960-74
86. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48(2): 442-8
87. Yoneda M Yoneda M Mawatari H et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD Dig Liver Dis 2008 40 5 371-8
88. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51(2): 454-62
89. Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256(2): 640-7
90. Lupsor M, Badea R, Stefanescu H, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19(1): 53-60
91. Petta S, Di Marco V, Camma C, et al. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33(12): 1350-60
92. Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54(1): 64-71
93. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55(1): 199-208
94. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107(12): 1862-71
95. Mahadeva S, Mahfudz AS, Vijayanathan A, et al. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. J Dig Dis 2013; 14(11): 604-10
96. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51(3): 828-35
97. Roulot D, Costes JL, Buyck JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60(7): 977-84
98. Suzuki K, Yoneda M, Imajo K, et al. Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. Hepatol Res 2013; 43(9): 979-83
99. Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11(12): 1573-84
100. Colecchia A, Montrone L, Scaioli E, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012; 143(3): 646-54
101. Osaki A, Kubota T, Suda T, et al. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World J Gastroenterol 2010; 16(23): 2918-25
102. Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55(3): 666-72
103. Ochi HM, Hirooka Y, Koizumi Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012; 56(4): 1271-8
104. Poynard T, Munteanu M, Luckina E, et al. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol 2013; 58(5): 928-35
105. Cassinotto C,Lapuyade B, Mouries A, et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol 2014; 61(3): 550-7
106. Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50(5): 923-8
107. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10(6): 330-44
108. Loria P, Marchesini G, Nascimbeni F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014; 232(1): 99-109
109. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005; 11(31): 4838-42
110. Açikel M, Sunay S, Koplay M, et al. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg 2009; 9(4): 273-9
111. Lee YH,Wu YJ, Liu CC, et al. The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification. Radiol Res Pract 2011; 2011: 586785
112. Boddi M, Tarquini R, Chiostri M, et al. Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest 2013; 43(5): 429-38
113. Inci MF, Özkan F, Ark B, et al. Sonographic evaluation for predicting the presence and severity of coronary artery disease. Ultrasound Q 2013; 29(2): 125-30
114. Choi DH, Lee SJ, Kang CD, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol 2013; 19(38): 6453-7
115. Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open 2014; 4(3): e004973
116. Pacifico L, Cantisani V, Ricci P, et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008; 63(4): 423-7
117. Mohammadi A, Bazazi A, Maleki-Miyandoab T, Ghasemi-Rad M. Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding. Int J Clin Exp Med 2012; 5(3): 251-6
118. Li X, Xia M, Ma H, et al. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis 2012; 224(2): 480-5
119. Hamirani YS, Pandey S, Rivera JJ, et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 2008; 201(1): 1e7
120. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49(4): 600-7
121. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 2013; 230(2): 258-67
122. Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med 2010; 122(1): 10e8
123. Lonardo A, Lombardini S, Scaglioni F, et al. Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol 2006; 12(36): 5826-33
124. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90
125. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51(5): 1820-32
126. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64(5): 1263-72
127. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53(3): 1020-2
128. European Association for the Study of the Liver, European Organisation for Researchand Treatment of Cancer. EASL E-ORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56(4): 908-43
129. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4(2): 439-74
130. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23(1): 47-58
131. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132(7): 2557-76
132. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51(6): 1972-8
133. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain?. J Gen Intern Med 1994; 9(12): 702-7
134. Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma: a standard of care, not a clinical option. Hepatology 2011; 54(6): 1898-900
135. Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21(5): 793-9
136. Kubota K, Ina H, Okada Y, Irie T. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003; 48(3): 581-6
137. Singal A, Volk ML, Waljee A, et al. Metaanalysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30(1): 37-47
138. Giannini EG, Marenco S, Borgonovo G, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012; 56(4): 1371-9
139. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54(6): 1987-97
140. Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig Liver Dis 2010; 42(S3): 228-34
141. Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34(1): 11-29
142. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42(1): 27-34
143. Kudo M, Izumi N, Kokudo N et al. Management of hepatocellular carcinoma in Japan: consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29(3): 339-64
144. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51(6): 2020-9
145. Tarantino L, Francica G, Sordelli I, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging 2006; 31(5): 537-44
146. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59(5): 638-44
147. Buscarini L, Fornari F, Bolondi L, et al. Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol 1990; 11(3): 344-8
148. Lee MW, Rhim H, Cha DI, et al. Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1-3 cm): value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol 2013; 24(7): 958-65
149. Park HJ, Lee MW, Lee MH, et al. Fusion imaging-guided percutaneous biopsy of focal hepatic lesions with poor conspicuity on conventional sonography. J Ultrasound Med 2013; 32(9): 1557-64
150. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008; 47(1): 82-9
151. Francica G, Saviano A, De Sio I, et al. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis 2013; 45(4): 336-41
152. Pompili M, Saviano A, De Matthaeis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma '3 cm. Results of a multicenter Italian survey. J Hepatol 2013 (1): 89-97
153. Wu F, Wang ZB, Chen WZ, et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol 2004; 11(12): 1061-9
154. Cheung TT, Chu FS, Jenkins CR, et al. Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. World J Surg 2012; 36(10): 2420-7
155. Kleiner DE Brunt EM Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 6 1313-21
156. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1): 91-100
157. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467-74
158. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51(3): 606